Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00313001
Status:
COMPLETED
Last Update Posted:
2017-01-06
First Post:
2006-04-08
Brief Title:
Effects of Biphasic Insulin Aspart 7030 vs Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Effects of NovoLog Mix 7030 Biphasic Insulin Aspart 7030 BID and QD vs Byetta Exenatide BID on Glycemic Control A Multicenter 24-Week Open-Label Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is conducted in the United States of America USA The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 7030 once or twice daily to patients receiving exenatide twice daily Patients enrolled in the study will be insulin naive patients who have not achieved glycemic control with metformin and sulfonylurea
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None